Croda strengthens position in life sciences with $185 million acquisition of Avanti Polar Lipids

LONDON: Croda International Plc announced that it has agreed to acquire Avanti Polar Lipids Inc., a knowledge-intensive leader in lipid-based drug delivery technologies for next generation pharmaceuticals. Croda has acquired Avanti for an initial consideration of $185 million on a debt and cash-free basis, with an additional earnout of up to $75m based on near-term…